Cargando…

5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population

Fluoropyrimidines represent the backbone of many chemotherapy protocols and the standard treatment for many types of tumors. Toxicity associated with fluoropyrimidines can occur in up to 40% of cases. BACKGROUND AND PURPOSE: The objective of this study was to analyze the correlation between the plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Deac, Andrada-Larisa, Pop, Raluca Maria, Burz, Claudia Cristina, Bocşan, Ioana Corina, Militaru, Claudia, Suciu, Şoimiţa, Buzoianu, Anca Dana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iuliu Hatieganu University of Medicine and Pharmacy 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642744/
https://www.ncbi.nlm.nih.gov/pubmed/37970190
http://dx.doi.org/10.15386/mpr-2643
_version_ 1785147013647564800
author Deac, Andrada-Larisa
Pop, Raluca Maria
Burz, Claudia Cristina
Bocşan, Ioana Corina
Militaru, Claudia
Suciu, Şoimiţa
Buzoianu, Anca Dana
author_facet Deac, Andrada-Larisa
Pop, Raluca Maria
Burz, Claudia Cristina
Bocşan, Ioana Corina
Militaru, Claudia
Suciu, Şoimiţa
Buzoianu, Anca Dana
author_sort Deac, Andrada-Larisa
collection PubMed
description Fluoropyrimidines represent the backbone of many chemotherapy protocols and the standard treatment for many types of tumors. Toxicity associated with fluoropyrimidines can occur in up to 40% of cases. BACKGROUND AND PURPOSE: The objective of this study was to analyze the correlation between the plasma concentration of 5-fluorouracil and the adverse events that patients might experience during this therapy. METHODS: A total of 58 patients received 5-fluorouracil-based chemotherapy. A blood sample was collected from each patient during the drug infusion, in order to assess the area under the curve for 5-fluorouracil. The occurring adverse events were evaluated through medical recordings of the patients’ reported symptoms, clinical and paraclinical examinations. RESULTS: In our study, the majority of patients experienced some type of toxicity. Moreover, we found a correlation between 5-FU plasma concentration (expressed as AUC) and adverse events, a stronger one with hematological adverse reactions and a weaker one with gastrointestinal and cardiovascular toxicity. CONCLUSION: Determining the plasma concentration of 5-FU in patients with severe toxicities could represent a method of individualizing the treatment and improving the safety profile.
format Online
Article
Text
id pubmed-10642744
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Iuliu Hatieganu University of Medicine and Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-106427442023-11-15 5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population Deac, Andrada-Larisa Pop, Raluca Maria Burz, Claudia Cristina Bocşan, Ioana Corina Militaru, Claudia Suciu, Şoimiţa Buzoianu, Anca Dana Med Pharm Rep Original Research: Pharmacology Fluoropyrimidines represent the backbone of many chemotherapy protocols and the standard treatment for many types of tumors. Toxicity associated with fluoropyrimidines can occur in up to 40% of cases. BACKGROUND AND PURPOSE: The objective of this study was to analyze the correlation between the plasma concentration of 5-fluorouracil and the adverse events that patients might experience during this therapy. METHODS: A total of 58 patients received 5-fluorouracil-based chemotherapy. A blood sample was collected from each patient during the drug infusion, in order to assess the area under the curve for 5-fluorouracil. The occurring adverse events were evaluated through medical recordings of the patients’ reported symptoms, clinical and paraclinical examinations. RESULTS: In our study, the majority of patients experienced some type of toxicity. Moreover, we found a correlation between 5-FU plasma concentration (expressed as AUC) and adverse events, a stronger one with hematological adverse reactions and a weaker one with gastrointestinal and cardiovascular toxicity. CONCLUSION: Determining the plasma concentration of 5-FU in patients with severe toxicities could represent a method of individualizing the treatment and improving the safety profile. Iuliu Hatieganu University of Medicine and Pharmacy 2023-10 2023-10-26 /pmc/articles/PMC10642744/ /pubmed/37970190 http://dx.doi.org/10.15386/mpr-2643 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
spellingShingle Original Research: Pharmacology
Deac, Andrada-Larisa
Pop, Raluca Maria
Burz, Claudia Cristina
Bocşan, Ioana Corina
Militaru, Claudia
Suciu, Şoimiţa
Buzoianu, Anca Dana
5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population
title 5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population
title_full 5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population
title_fullStr 5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population
title_full_unstemmed 5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population
title_short 5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population
title_sort 5-fluorouracil therapeutic drug monitoring and adverse events in a romanian population
topic Original Research: Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642744/
https://www.ncbi.nlm.nih.gov/pubmed/37970190
http://dx.doi.org/10.15386/mpr-2643
work_keys_str_mv AT deacandradalarisa 5fluorouraciltherapeuticdrugmonitoringandadverseeventsinaromanianpopulation
AT popralucamaria 5fluorouraciltherapeuticdrugmonitoringandadverseeventsinaromanianpopulation
AT burzclaudiacristina 5fluorouraciltherapeuticdrugmonitoringandadverseeventsinaromanianpopulation
AT bocsanioanacorina 5fluorouraciltherapeuticdrugmonitoringandadverseeventsinaromanianpopulation
AT militaruclaudia 5fluorouraciltherapeuticdrugmonitoringandadverseeventsinaromanianpopulation
AT suciusoimita 5fluorouraciltherapeuticdrugmonitoringandadverseeventsinaromanianpopulation
AT buzoianuancadana 5fluorouraciltherapeuticdrugmonitoringandadverseeventsinaromanianpopulation